SELAS PHARMACIE MANTES SULLY is a French company
founded 13 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MANTES-LA-JOLIE (78200),
this company of category PME
shows in 2018 a revenue of 1.7 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE MANTES SULLY (SIREN 792297756)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
1 744 091 €
1 472 738 €
N/C
Net income
109 474 €
318 700 €
318 700 €
386 142 €
97 118 €
97 714 €
62 997 €
81 624 €
114 121 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
183 360 €
110 672 €
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
3.6%
5.5%
N/C
Revenue and income statement
In 2024, SELAS PHARMACIE MANTES SULLY generates positive net income of 109 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 114 k€ -> 109 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
109 474 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 120%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 32%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
120.282%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
31.744%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
1144.331
357.47
244.502
147.988
105.565
64.419
65.777
65.777
120.282
Financial autonomy
5.408
12.655
18.249
30.353
35.3
46.709
42.648
42.648
31.744
Repayment capacity
None
4.959
3.609
None
None
None
None
None
None
Cash flow / Revenue
None%
6.173%
7.343%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
120.282024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Average+20 pts over 3 years
In 2024, the debt ratio of SELAS PHARMACIE MANTES SULLY (120.28) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
31.74%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average-16 pts over 3 years
In 2024, the financial autonomy of SELAS PHARMACIE MANTES SULLY (31.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 192.48. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
104.26
105.071
120.702
152.648
166.619
279.354
219.627
219.627
192.483
Interest coverage
None
12.286
19.975
None
None
None
None
None
None
Sector positioning
Liquidity ratio
192.482024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of SELAS PHARMACIE MANTES SULLY (192.48) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 10995 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1044 days. The gap of 9951 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
10995 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
1044 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS PHARMACIE MANTES SULLY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
164 240 €
177 391 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
0
31
30
0
0
0
0
0
0
Customer payment term (days)
103
11
5
171
139
226
539
539
10995
Supplier payment term (days)
1547
104
92
945
920
1027
1272
1272
1044
Positioning of SELAS PHARMACIE MANTES SULLY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELAS PHARMACIE MANTES SULLY is estimated at
1 528 337 €
(range 1 064 310€ - 2 286 481€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1064k€1528k€2286k€
1 528 337 €Range: 1 064 310€ - 2 286 481€
NAF 5 année 2024
Valuation method used
Net Income Multiple
109 474 €
×
14.0x
=1 528 338 €
Range: 1 064 310€ - 2 286 481€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE MANTES SULLY with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE MANTES SULLY
What is the revenue of SELAS PHARMACIE MANTES SULLY ?
The revenue of SELAS PHARMACIE MANTES SULLY in 2018 is 1.7 M€.
Is SELAS PHARMACIE MANTES SULLY profitable?
Yes, SELAS PHARMACIE MANTES SULLY generated a net profit of 109 k€ in 2024.
Where is the headquarters of SELAS PHARMACIE MANTES SULLY ?
The headquarters of SELAS PHARMACIE MANTES SULLY is located in MANTES-LA-JOLIE (78200), in the department Yvelines.
Where to find the tax return of SELAS PHARMACIE MANTES SULLY ?
The tax return of SELAS PHARMACIE MANTES SULLY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE MANTES SULLY operate?
SELAS PHARMACIE MANTES SULLY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart